Clinical trials: Neoplasm, Liver
Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer
This phase II trial studies how well cabozantinib and pembrolizumab work for the first-line treatment of patients with liver cancer who are not eligible for local therapy (i.e. advanced stage).
- Conditions
- Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
- Trial name
- NCT04442581
- Testing
- Cabozantinib S-malate, Pembrolizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Washington
Carcinoma, Hepatocellular
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
The purpose of this study is: evaluate the safety and activity of administering arsenic trioxide (Trisenox) in the treatment of unresectable or metastatic primary liver cancer, to evaluate the qualitative and quantitative…
- Trial name
- NCT00582400
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Hepatocellular Cancer, AFP Expressing Tumors
AFPᶜ³³²T in Advanced HCC
This first time in human study is intended for men and women between 18 and 75 years of age who have advanced liver cancer which has grown or returned after being treated or another AFP expressing tumor.
- Trial name
- NCT03132792
- Testing
- Autologous genetically modified AFPᶜ³³²T cells
- Where
- 21 sites in United States, France and 2 more
- Volunteers
- 39 people
- Sponsor
- Adaptimmune
Human Papillomavirus, Human Immunodeficiency Virus
Increasing Uptake of Evidence-Based Screening Services Through CHW-led Multi-modality Intervention
The purpose of this research study is to determine the best way to increase screening for cervical cancer, colorectal cancer, HIV, and Hepatitis C among under screened Hispanic, Haitian and African-American individuals in…
- Conditions
- Human Papillomavirus, Human Immunodeficiency Virus, Hepatitis C, ColoRectal Cancer
- Trial name
- NCT02970136
- Testing
- OraQuick Swab, Fecal Immunochemical Test, OraQuick Fingerstick
- Where
- United States
- Volunteers
- 754 people, healthy volunteers welcome
- Sponsor
- University of Miami
Hepatocellular Carcinoma, Chemoembolization
TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve
TACE is frequently offered to patients with baseline hepatic dysfunction with the purpose of diminishing hepatic tumor burden while patients await transplantation.
- Trial name
- NCT02147301
- Testing
- LC Bead
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, San Francisco
Advanced Primary Liver Cancer, Advanced Biliary Tract Carcinoma
A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC
This an open-label，Non-Randominzed Phase 2 study to evaluate the Safety and Tolerability of SHR-1210 in combination with Apatinib or chemotherapy (FOLFOX4 or GEMOX regimen) in subjects with Advanced PLC.or BTC Participants with…
- Trial name
- NCT03092895
- Testing
- SHR-1210, Apatinib, FOLFOX4
- Where
- 7 sites in China
- Volunteers
- 157 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hepatocellular Carcinoma
Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC
Hepatocellular carcinoma (HCC) is a common disease with high mortality. More than 80% patients receive a diagnosis when their tumors are too advanced for curative approaches and have a dismal prognosis.
- Trial name
- NCT04011033
- Testing
- iNKT cells, Human recombinated Interleukin-2, TAE/TACE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing YouAn Hospital
Advanced Hepatocellular Carcinoma (HCC)
MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients
This study consists of two parts: Phase I is a dose escalation study to determine the Recommended Phase II Dose (RP2D) of MGD013 monotherapy and that of MGD013 when in combination with Brivanib Alaninate (ZL-2301) in subjects…
- Trial name
- NCT04212221
- Testing
- MGD013 monotherapy, MGD013 in combination with Brivanib Alaninate
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Liver Metastases, Lung Metastases
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
This phase II trial studies the effectiveness of the combination of stereotactic radiation therapy and ipilimumab in patients with metastatic melanoma that has spread to four or fewer sites in the body (oligometastatic).
- Conditions
- Liver Metastases, Lung Metastases, Recurrent Melanoma, Stage IV Melanoma
- Trial name
- NCT02107755
- Testing
- ipilimumab, stereotactic radiosurgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Stage IV Uveal Melanoma
SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver
The purpose of this study is to determine whether radiation provided locally to the liver tumor vasculature environment will demonstrate a response of tumor decline. This radiation may cause the tumor cells to die.
- Trial name
- NCT01473004
- Testing
- Sir-Spheres®
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Thomas Jefferson University
Metastatic Breast Cancer, Liver Metastases
Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease
This is a phase II trial evaluating intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic capecitabine and in patients with a HER2-positive tumour in combination with trastuzumab (Herceptin®)…
- Trial name
- NCT01387295
- Testing
- oxaliplatin, capecitabine, trastuzumab
- Where
- Denmark
- Volunteers
- 38 people
- Sponsor
- Dorte Nielsen
Hepatocellular Carcinoma, Nonalcoholic Steatohepatitis
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver.
- Trial name
- NCT04550481
- Testing
- Biospecimen Collection, Lisinopril, Liver Ultrasonographic Elastography
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Northwestern University
Hepatocellular Carcinoma
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
The primary goal of this study is to gather efficacy data concerning the progression-free survival rate with electromagnetic fields plus Regorafenib when compared to historical data with Regorafenib alone as a second-line therapy…
- Trial name
- NCT04327700
- Testing
- TheraBionic, Regorafenib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Wake Forest University Health Sciences
Stage III Intrahepatic Cholangiocarcinoma, Stage IVA Intrahepatic Cholangiocarcinoma
Radiation Therapy vs. Observation Following Gemcitabine and Cisplatin for Inoperable Localized Liver Cancer
This randomized phase III trial studies how well gemcitabine hydrochloride and cisplatin with or without radiation therapy work in treating patients with localized liver cancer that cannot be removed by surgery.
- Trial name
- NCT02200042
- Testing
- Image Guided Radiation Therapy
- Where
- 34 sites in United States, Canada
- Volunteers
- 1 people
- Sponsor
- NRG Oncology
Advanced Solid Tumors
An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols
This is an extension study that will allow participants to continue to receive study therapy when the original studies into which they were enrolled have reached their designated end-dates.
- Trial name
- NCT01178411
- Testing
- Tivantinib, Anti-Cancer Combination Therapy
- Volunteers
- 60 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Carcinoma, Hepatocellular
A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
The purpose of the study is: Find out if patients receiving sorafenib will live longer. Find out if sorafenib has any effect on patient reported outcomes.
- Trial name
- SHARP (NCT00105443)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 178 sites in United States, Argentina and 21 more
- Volunteers
- 602 people
- Sponsor
- Bayer
Hepatocellular Cancer
Sharing Decision-making Program for HCC Patients Treatment Decisions
Aim: Explore the effectiveness of sharing decision-making program interventions in the early stage of HCC to reduce treatment decisions conflicts and improving decision-making satisfaction.
- Trial name
- NCT03926039
- Testing
- sharing decision-making program
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- National Taipei University of Nursing and Health Sciences
Hepatic Cancer
A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy
This phase II study aims to evaluate regional chemotherapy in patients with unresectable primary hepatic malignancy. Specifically, eligible patients with hepatocellular carcinoma and peripheral cholangiocarcinoma, considered…
- Trial name
- NCT00587067
- Testing
- FLOXURIDINE
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Liver Cancer
Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II
The most frequently used products in CHE are doxorubicin (36%), cisplatin (31%), and epirubicin (12%). But until recently, there were no obvious reasons to use one product over another.
- Trial name
- IDASPHERE II (NCT02185768)
- Testing
- idarubicin, Dc- Beads 300-500µm
- Where
- 7 sites in France
- Volunteers
- 46 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
This phase II trial is studying how well AZD2171 works in treating patients with locally advanced unresectable or metastatic liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00427973
- Testing
- cediranib maleate, laboratory biomarker analysis, computed tomography
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)